To synthesize the available evidence on medical therapies investigated for the management of NF2-related vestibular schwannomas (VS).
No single medical therapy has strong enough evidence to change standard practice yet; clinicians managing NF2-related vestibular schwannomas should await higher-quality trials before routinely adopting pharmacological alternatives to surgery or radiation.
NF2-related schwannomatosis is a leading cause of bilateral hearing loss in young adults, and a rigorous synthesis of medical therapy evidence is critical for guiding treatment decisions in the absence of curative options.
- 01Systematic review in Otology & Neurotology synthesizes all current evidence on medical therapies for NF2-related vestibular schwannomas.
- 02NF2-related schwannomatosis causes bilateral tumors on hearing/balance nerves, often leading to profound deafness.
- 03Medical (non-surgical, non-radiation) treatment options remain limited and evidence quality varies.
- 04Published ahead of print June 2026; findings reflect the most up-to-date synthesis available.
- 05Results will likely inform future clinical guidelines and trial design for this rare condition.
Current medical therapies for NF2-related vestibular schwannomas have a defined evidence base that can be systematically summarized.
studypartially supported- PMID
- 42276040
- DOI
- 10.1097/MAO.0000000000004968.
- Journal
- Otology & Neurotology
- Publication type
- systematic_review
- Evidence level
- 1a
- Population
- Patients with NF2-related schwannomatosis (neurofibromatosis type 2) and associated vestibular schwannomas
- Intervention
- Medical (pharmacological) therapies for NF2-related vestibular schwannomas
Primary outcomes
Tumor response to medical therapy; Hearing preservation; Treatment safety and tolerability